Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797336 · ClinicalTrials.gov registry record · Phase 1
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by PAQ Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 7
- Study locations
NCT06797336: Recruiting Phase 1 study of Solid Tumor, sponsored by PAQ Therapeutics.
NCT06797336 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by PAQ Therapeutics. The registered enrollment target is 115 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (48% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06797336, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by PAQ Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.
Conditions Studied
Interventions
- DRUG PT0253
Study Locations (7)
Tennessee
- SCRI Lake Mary - Nashville
- SCRI Oncology Partners - Nashville
Texas
- New Experimental Therapeutics of San Antonio LLC - San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC - San Antonio
Massachusetts
- Dana Farber/Massachusetts General Hospital, Inc - Boston
Utah
- START Mountain Region - West Valley City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2027-06-16 |
| Phase | Phase 1 |
What NCT06797336 shows while recruiting
NCT06797336 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PT0253 is the first listed.
NCT06797336 lists 7 locations in 5 states (Tennessee, Texas, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06797336 about?
NCT06797336 is a clinical study titled "A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors". The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherap...
What is the current status of trial NCT06797336?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2024-12-19. Estimated completion is 2027-06-16.
What conditions does trial NCT06797336 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06797336?
The interventions under investigation include: PT0253 (DRUG).
Who is sponsoring clinical trial NCT06797336?
This trial is sponsored by PAQ Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797336 being conducted?
This trial has 7 study locations across Massachusetts, Tennessee, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06797336's enrollment target sits among peer trials
115 79th of 196 higher than 118 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI